Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections

Bradley J. Gardiner, Yoav Golan

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Avibactam, a novel β-lactamase inhibitor, has recently been co-formulated with ceftazidime and approved for use in patients with complicated intra-abdominal and urinary tract infections, where no better treatment alternative exists. The basis for its FDA approval has been the extensive clinical experience with ceftazidime and the demonstration in vitro and in animal models that the addition of avibactam reverses resistance to ceftazidime in extended-spectrum β-lactamase and some carbapenemase-producing Enterobacteriaceae. Early clinical data are promising, with efficacy demonstrated in patients with complicated intra-abdominal and urinary tract infections. This review will summarize the in vitro, animal and clinical data available on this agent to date.

Original languageEnglish
Pages (from-to)451-463
Number of pages13
JournalExpert Review of Anti-Infective Therapy
Volume14
Issue number5
DOIs
StatePublished - 3 May 2016
Externally publishedYes

Keywords

  • Ceftazidime-avibactam
  • Gram-negative infection
  • antibiotic resistance
  • carbapenem-resistant Enterobacteriaceae
  • β-lactamase
  • β-lactamase inhibitor

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections'. Together they form a unique fingerprint.

Cite this